Reduced Glucocorticoid Noninferior to High-dose Regimen in ANCA-associated Vasculitis

According to the researchers, 71% of participants in the reduced-dose group who completed the trial achieved remission at 6 months, compared with 69.2% of those in the high-dose group. In this recently published study in JAMA, Furuta and colleagues demonstrate that "reduced dose" steroid (...

Full description

Saved in:
Bibliographic Details
Published inHealio Rheumatology pp. 42 - 43
Main Authors Laster, Andrew J, Laday, Jason
Format Trade Publication Article
LanguageEnglish
Published Thorofare SLACK INCORPORATED 01.08.2021
Subjects
Clinical trials
COVID-19
Disease
Drug dosages
Hemorrhage
Immunosuppressive agents
Infections
Patients
Remission (Medicine)
Steroids
Japan
Online AccessGet full text

Cover

More Information
Summary:According to the researchers, 71% of participants in the reduced-dose group who completed the trial achieved remission at 6 months, compared with 69.2% of those in the high-dose group. In this recently published study in JAMA, Furuta and colleagues demonstrate that "reduced dose" steroid (prednisolone) plus rituximab was noninferior to a "high dose" steroid plus rituximab in treatment of ANCA associated vasculitis. [...]there were significantly fewer serious adverse events (SAEs) and serious infections in the "reduced dose" arm. [...]the total cumulative dose was greater: A mean of 3595 mg in the RAVE trial vs. median of 1318 in the reduced-dose steroid arm in the Furuta trial).
ISSN:2380-6818
2380-6834